Adamas Pharmaceuticals (ADMS) Upgraded at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Adamas Pharmaceuticals (NASDAQ:ADMS) from a sell rating to a hold rating in a research note released on Tuesday.

According to Zacks, “Adamas Pharmaceuticals, Inc. is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company seeks to achieve this by modifying the pharmacokinetic profiles of approved drugs to create novel therapeutics for use alone and in fixed-dose combination products. Adamas is currently developing ADS-5102, its lead wholly-owned product candidate, for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease and for the treatment of major symptoms associated with multiple sclerosis in patients with walking impairment. The company’s portfolio also includes Namzaric and Namenda XR, two approved products with Forest Laboratories Holdings Limited, an indirect wholly-owned subsidiary of Allergan plc. Forest is responsible for marketing both products in the United States under an exclusive license from Adamas. “

ADMS has been the topic of a number of other research reports. Mizuho restated a hold rating and set a $11.00 price target on shares of Adamas Pharmaceuticals in a report on Friday, January 11th. Leerink Swann started coverage on Adamas Pharmaceuticals in a report on Monday, November 12th. They set an outperform rating and a $20.00 price target on the stock. BidaskClub upgraded Adamas Pharmaceuticals from a strong sell rating to a sell rating in a report on Friday, February 15th. Needham & Company LLC downgraded Adamas Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday. Finally, HC Wainwright set a $40.00 price target on Adamas Pharmaceuticals and gave the company a buy rating in a report on Monday, January 14th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company. The company presently has an average rating of Hold and an average target price of $23.88.

Shares of NASDAQ:ADMS opened at $8.16 on Tuesday. Adamas Pharmaceuticals has a 1 year low of $7.42 and a 1 year high of $32.90. The stock has a market cap of $303.70 million, a P/E ratio of -2.06 and a beta of 1.41. The company has a current ratio of 8.95, a quick ratio of 8.74 and a debt-to-equity ratio of 1.01.

Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings results on Monday, March 4th. The specialty pharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.36) by $0.30. Adamas Pharmaceuticals had a negative return on equity of 106.74% and a negative net margin of 617.27%. On average, analysts expect that Adamas Pharmaceuticals will post -5.21 earnings per share for the current fiscal year.

Several hedge funds have recently bought and sold shares of the business. First Mercantile Trust Co. grew its holdings in shares of Adamas Pharmaceuticals by 43.2% during the 4th quarter. First Mercantile Trust Co. now owns 5,765 shares of the specialty pharmaceutical company’s stock worth $49,000 after acquiring an additional 1,740 shares during the period. Fisher Asset Management LLC grew its holdings in shares of Adamas Pharmaceuticals by 2.8% during the 4th quarter. Fisher Asset Management LLC now owns 121,459 shares of the specialty pharmaceutical company’s stock worth $1,037,000 after acquiring an additional 3,342 shares during the period. Bingham Osborn & Scarborough LLC grew its holdings in shares of Adamas Pharmaceuticals by 3.0% during the 4th quarter. Bingham Osborn & Scarborough LLC now owns 134,108 shares of the specialty pharmaceutical company’s stock worth $1,145,000 after acquiring an additional 3,850 shares during the period. AXA grew its holdings in shares of Adamas Pharmaceuticals by 2.2% during the 3rd quarter. AXA now owns 190,830 shares of the specialty pharmaceutical company’s stock worth $3,820,000 after acquiring an additional 4,037 shares during the period. Finally, Advisor Group Inc. grew its holdings in shares of Adamas Pharmaceuticals by 252.0% during the 4th quarter. Advisor Group Inc. now owns 6,300 shares of the specialty pharmaceutical company’s stock worth $54,000 after acquiring an additional 4,510 shares during the period. Hedge funds and other institutional investors own 79.76% of the company’s stock.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its partnered approved/commercial products include Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease.

Featured Story: Does the Step Transaction Doctrine Affect a Backdoor Roth IRA?

Get a free copy of the Zacks research report on Adamas Pharmaceuticals (ADMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Adamas Pharmaceuticals  Upgraded at Zacks Investment Research
Adamas Pharmaceuticals Upgraded at Zacks Investment Research
Connable Office Inc. Acquires 1,613 Shares of Investors Bancorp Inc
Connable Office Inc. Acquires 1,613 Shares of Investors Bancorp Inc
Constellation Pharmaceuticals  Downgraded by Zacks Investment Research to Hold
Constellation Pharmaceuticals Downgraded by Zacks Investment Research to Hold
Blackrock Capital Investment  Downgraded by Zacks Investment Research to “Sell”
Blackrock Capital Investment Downgraded by Zacks Investment Research to “Sell”
U.S. Auto Parts Network  Given a $5.00 Price Target by Barrington Research Analysts
U.S. Auto Parts Network Given a $5.00 Price Target by Barrington Research Analysts
Eagle Asset Management Inc. Has $3.99 Million Stake in BioSpecifics Technologies Corp.
Eagle Asset Management Inc. Has $3.99 Million Stake in BioSpecifics Technologies Corp.


Leave a Reply

 
© 2006-2019 Zolmax.